Xatral SR

Xatral SR may be available in the countries listed below.

Ingredient matches for Xatral SR

Alfuzosin

Alfuzosin is reported as an ingredient of Xatral SR in the following countries:

• Australia


• Lithuania

International Drug Name Search

L-Thyroxine SERB

L-Thyroxine SERB may be available in the countries listed below.

Ingredient matches for L-Thyroxine SERB

Levothyroxine

Levothyroxine sodium salt (a derivative of Levothyroxine) is reported as an ingredient of L-Thyroxine SERB in the following countries:

• France

International Drug Name Search

Bezafibrat Arcana

Bezafibrat Arcana may be available in the countries listed below.

Ingredient matches for Bezafibrat Arcana

Bezafibrate

Bezafibrate is reported as an ingredient of Bezafibrat Arcana in the following countries:

• Austria

International Drug Name Search

Levofloxacina Farmoz

Levofloxacina Farmoz may be available in the countries listed below.

Ingredient matches for Levofloxacina Farmoz

Levofloxacin

Levofloxacin is reported as an ingredient of Levofloxacina Farmoz in the following countries:

• Portugal

International Drug Name Search

Kerato Biciron

Kerato Biciron may be available in the countries listed below.

Ingredient matches for Kerato Biciron

Calcium Pantothenate

Calcium Pantothenate is reported as an ingredient of Kerato Biciron in the following countries:

• Germany

International Drug Name Search

Nexplanon

Nexplanon is a brand name of etonogestrel, approved by the FDA in the following formulation(s):

NEXPLANON (etonogestrel - implant; implantation)

• 
  Manufacturer: ORGANON USA INC
  
  Approval date: May 31, 2011
  
  Strength(s): 68MG/IMPLANT ^[RLD]

Has a generic version of Nexplanon been approved?

No. There is currently no therapeutically equivalent version of Nexplanon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexplanon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Nexplanon.

See also...

• Nexplanon Advanced Consumer Information (Micromedex)
• Etonogestrel implant Consumer Information (Cerner Multum)
• Etonogestrel Intradermal Advanced Consumer Information (Micromedex)

Kebirzol

Kebirzol may be available in the countries listed below.

Ingredient matches for Kebirzol

Letrozole

Letrozole is reported as an ingredient of Kebirzol in the following countries:

• Argentina

International Drug Name Search

Apo-Diltiaz

Apo-Diltiaz may be available in the countries listed below.

Ingredient matches for Apo-Diltiaz

Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Apo-Diltiaz in the following countries:

• Canada


• Vietnam

International Drug Name Search

Bovatec 150 FP

Dosage Form: FOR ANIMAL USE ONLY
Bovatec®

150 FP

Brand of lasalocid

Type A Medicated Article

Active ingredient

Each pound contains 150 grams (33.1%) of lasalocid (as lasalocid sodium activity) in a carrier suitable for incorporation in feed.

Important

Handling Information - Must be thoroughly mixed in feeds before use. When mixing and handling lasalocid premix, use protective clothing, impervious gloves and a dust mask. Avoid contact with eyes. Operators should wash hands thoroughly with soap and water after handling.

Mixing directions

This product should be further diluted in an intermediate blending step prior to mixing in the final feed. Do not feed undiluted.

1.

Complete Feed

a.

Intermediate blending: Mix 1 part of Bovatec 150 FP (Type A Medicated Article) with 29 parts of finely ground nonmedicated feedstuffs to provide an intermediate premix containing 5 grams of lasalocid per pound.

b.

Using the 5 g/lb intermediate premix, the following table would apply to the manufacture of complete feeds:

Intended lasalocid concentration in the complete feed		Add the following amounts of 5 grams per pound intermediate premix per ton of complete feed mixed:
grams/ton	mg/lb	lbs/ton
* Maximum approved concentration for complete feeds for feedlot cattle and sheep in confinement
10	5	2
15	7.5	3
30*	15	6

 

 

c.

Using the 5 g/lb intermediate premix, the following table would apply to the manufacture of other complete feeds and supplements that do not require further mixing:

Daily feeding rate	Desired daily lasalocid intake	Add the following amounts of 5 grams per pound intermediate premix per ton of feed or supplement mixed:	Lasalocid will be present in the feed or supplement at the following concentration:
lbs/head/day	mg/head/day	lbs/ton	grams/ton
1	60	24	120
	200	80	400
	300	120	600
2	60	12	60
	200	40	200
	300	60	300
3	60	8	40
	200	26.7	133.5
	300	40	200

2.

Dry Supplement

a.

Intermediate blending: Mix 1 part Bovatec 150 FP premix (Type A Medicated Article) with 6.5 parts of finely ground nonmedicated feedstuffs to provide an intermediate premix containing 20 grams of lasalocid per pound. For example, mix one 50 lb bag of Bovatec 150 FP premix with 325 lbs of non-medicated feedstuffs.

b.

Using the 20 g/lb intermediate premix, the following table would apply to the manufacture of dry supplements:

Intended lasalocid concentration in the supplement		Add the following amounts of 20 grams per pound intermediate premix per ton of supplement mixed:
grams/ton	mg/lb	lbs/ton
400	200	20
600	300	30
1000	500	50
1440	720	72
1600	800	80

 

 

c.

Thoroughly mix supplement with sufficient non-medicated feedstuffs in accordance with the feeding rates listed in the use directions below.

3.

Liquid Supplement Intended for Addition to Dry Feeds

a.

Supplements with suspending agent(s) should be in a pH range of 4-8 and maintain physical stability for up to three months with a viscosity not less than 300 cps.

b.

Conventional liquid supplements should be in a pH range of 4-8.

 

For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

 

For liquid feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

Use directions

Species	Dose	Indications for use
Feedlot Cattle	10-30 grams lasalocid per ton of total ration (90% dry matter)	For improved feed efficiency in cattle being fed in confinement for slaughter, feed continuously to provide not less than 100 mg nor more than 360 mg per head per day.
	25-30 grams lasalocid per ton of total ration (90% dry matter)	For improved feed efficiency and increased rate of weight gain in cattle being fed in confinement for slaughter, feed continuously to provide not less than 250 mg nor more than 360 mg per head per day.
Pasture Cattle – slaughter, stocker, feeder cattle, and dairy and beef replacement heifers	60-300 mg lasalocid per head/day	For increased rate of weight gain. The drug must be contained in at least 1 pound of feed and fed continuously on a daily basis.
	60-300 mg lasalocid per head/day	For increased rate of weight gain, feed continuously on a free-choice basis. (Manufacture of Type C free-choice feeds from this product requires a Medicated Feed License Application approved by FDA.)
		Daily lasalocid intakes in excess of 200 mg per head per day have not been shown to be more effective than 200 mg lasalocid per head per day.
		NOTE: Coccidiosis may occur when young pasture cattle are co-mingled with adult cattle passing coccidial oocysts.
Cattle	1 mg lasalocid per 2.2 lbs body weight/day	For control of coccidiosis caused by Eimeria bovis and E. zuernii in cattle up to 800 lbs. Hand feed continuously to provide not more than 360 mg per day.
Sheep	20-30 grams lasalocid per ton of total ration (90% dry matter)	For prevention of coccidiosis caused by Eimeria ovina, E. crandallis, E. ovinoidalis (E. ninakohlyakimovae), E. parva, and E. intricata in sheep maintained in confinement. Feed continuously to provide not less than 15 mg nor more than 70 mg per head per day depending on body weight.

Caution

Animal Safety - Do not allow horses or other equines access to premixes or supplements containing lasalocid, as ingestion may be fatal. The safety of lasalocid in unapproved species has not been established. Feeding undiluted or mixing errors resulting in excessive concentrations of lasalocid could be fatal to cattle and sheep.

Warning

A withdrawal period has not been established for this product in pre-ruminating calves.

Do not use in calves to be processed for veal.

NADA 96-298, Approved by FDA. Not for human use.

Marketed by

Alpharma Inc.

Bridgewater, New Jersey 08807

Net wt 50 LB (22.68 kg)

Trademarks registered

by Alpharma Inc.

Made in USA

710316 0910

PRINCIPAL DISPLAY PANEL - 50 lb Bag

Bovatec®

150 FP

ALPHARMA

Brand of lasalocid

Type A Medicated Article

See back panel for use directions

Net wt 50 LB (22.68 kg)

ALPHARMA®

Bovatec®

150 FP

BOVATEC 150FP  lasalocid sodium  powder

Product Information Product Type OTC TYPE A MEDICATED ARTICLE ANIMAL DRUG NDC Product Code (Source) 46573-457 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lasalocid Sodium (Lasalocid) Lasalocid Sodium 150 g  in 0.45 kg

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color WHITE (white to tan) Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 46573-457-00 22.68 kg In 1 BAG None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA096298	01/01/2009

Labeler - Alpharma Inc. Animal Health (070954094)

Revised: 11/2009Alpharma Inc. Animal Health

Shacillin

Shacillin may be available in the countries listed below.

Ingredient matches for Shacillin

Ampicillin

Ampicillin is reported as an ingredient of Shacillin in the following countries:

• Iraq


• Yemen

International Drug Name Search

Conray

Conray is a brand name of iothalamate, approved by the FDA in the following formulation(s):

CONRAY (iothalamate meglumine - injectable; injection)

• 
  Manufacturer: MALLINCKRODT
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 60% ^[RLD]

Has a generic version of Conray been approved?

No. There is currently no therapeutically equivalent version of Conray available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Conray. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Conray.

See also...

Cofamix Oxytétracycline

Cofamix Oxytétracycline may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Cofamix Oxytétracycline

Oxytetracycline

Oxytetracycline is reported as an ingredient of Cofamix Oxytétracycline in the following countries:

• France

International Drug Name Search

Apo-Lansoprazole

Apo-Lansoprazole may be available in the countries listed below.

Ingredient matches for Apo-Lansoprazole

Lansoprazole

Lansoprazole is reported as an ingredient of Apo-Lansoprazole in the following countries:

• Canada

International Drug Name Search

Fisovin

Fisovin may be available in the countries listed below.

Ingredient matches for Fisovin

Griseofulvin

Griseofulvin is reported as an ingredient of Fisovin in the following countries:

• Bangladesh

International Drug Name Search

Diabesulf

Diabesulf may be available in the countries listed below.

Ingredient matches for Diabesulf

Glibenclamide

Glibenclamide is reported as an ingredient of Diabesulf in the following countries:

• Ecuador

International Drug Name Search

Paracétamol Codéine EG

Paracétamol Codéine EG may be available in the countries listed below.

Ingredient matches for Paracétamol Codéine EG

Codeine

Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Paracétamol Codéine EG in the following countries:

• France

Paracetamol

Paracetamol is reported as an ingredient of Paracétamol Codéine EG in the following countries:

• France

International Drug Name Search

Dompy

Dompy may be available in the countries listed below.

Ingredient matches for Dompy

Domperidone

Domperidone is reported as an ingredient of Dompy in the following countries:

• Bahrain


• Oman

International Drug Name Search

Lacorene

Lacorene may be available in the countries listed below.

Ingredient matches for Lacorene

Arginine

Arginine aspartate (a derivative of Arginine) is reported as an ingredient of Lacorene in the following countries:

• Argentina

International Drug Name Search

Lybrol

Lybrol may be available in the countries listed below.

Ingredient matches for Lybrol

Bisoprolol

Bisoprolol is reported as an ingredient of Lybrol in the following countries:

• Croatia (Hrvatska)

International Drug Name Search

Mastrinal

Mastrinal may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Mastrinal

Cloxacillin

Cloxacillin benzathine (a derivative of Cloxacillin) is reported as an ingredient of Mastrinal in the following countries:

• Switzerland

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Mastrinal in the following countries:

• Switzerland

International Drug Name Search

Famotin

Famotin may be available in the countries listed below.

Ingredient matches for Famotin

Famotidine

Famotidine is reported as an ingredient of Famotin in the following countries:

• Bangladesh


• Hong Kong


• India


• Singapore


• Sri Lanka

International Drug Name Search

Epizol

Epizol may be available in the countries listed below.

Ingredient matches for Epizol

Lamotrigine

Lamotrigine is reported as an ingredient of Epizol in the following countries:

• Romania

International Drug Name Search

Vetrocloricin

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vetrocloricin

Chloramphenicol

Chloramphenicol is reported as an ingredient of Vetrocloricin in the following countries:

• United States

International Drug Name Search

Zefecort

Zefecort may be available in the countries listed below.

Ingredient matches for Zefecort

Budesonide

Budesonide is reported as an ingredient of Zefecort in the following countries:

• Greece

International Drug Name Search

Bontril Slow-Release

Generic Name: phendimetrazine (Oral route)

fen-dye-MET-ra-zeen TAR-trate

Commonly used brand name(s)

In the U.S.

• Bontril


• Bontril PDM


• Bontril Slow-Release


• Melfiat


• Obezine


• Phendiet


• Phendiet-105


• Prelu-2

Available Dosage Forms:

• Tablet


• Capsule


• Capsule, Extended Release

Therapeutic Class: Appetite Suppressant, Centrally Acting

Chemical Class: Phendimetrazine

Uses For Bontril Slow-Release

Phendimetrazine is used as part of a short-term plan, along with a low calorie diet, for weight reduction. It is used in obese patients who have not been able to lose weight with diet and exercise alone. Phendimetrazine belongs to the group of medicines known as appetite suppressants.

This medicine is available only with your doctor's prescription.

Before Using Bontril Slow-Release

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of phendimetrazine tablets in the pediatric population. Safety and efficacy have not been established.

Use of phendimetrazine slow-release capsules is not recommended in children younger than 12 years of age.

Geriatric

No information is available on the relationship of age to the effects of phendimetrazine in geriatric patients.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

• Brofaromine


• Clorgyline


• Furazolidone


• Iproniazid


• Isocarboxazid


• Lazabemide


• Linezolid


• Moclobemide


• Nialamide


• Pargyline


• Phenelzine


• Procarbazine


• Rasagiline


• Selegiline


• Sibutramine


• Toloxatone


• Tranylcypromine

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Agitated state or


• Arteriosclerosis (hardening of the arteries), advanced or


• Drug abuse or dependence, history of or


• Glaucoma or


• Heart problems (e.g., heart murmur, valvular heart disease) or


• Hypertension (high blood pressure), moderate to severe or


• Hyperthyroidism (overactive thyroid)—Should not be used in patients with these conditions.

• Hypertension (high blood pressure), mild—Use with caution. May make these conditions worse.

Proper Use of phendimetrazine

This section provides information on the proper use of a number of products that contain phendimetrazine. It may not be specific to Bontril Slow-Release. Please read with care.

Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. If too much is taken, it may become habit-forming (causing mental or physical dependence).

This medicine is available in two forms: slow-release capsules and tablets. Ask your doctor which dosage form is right for you.

Carefully follow your doctor's instructions for a reduced-calorie diet plan and regular exercise. Talk with your doctor before starting any exercise program.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For treatment of obesity:
  
  • For oral dosage form (slow-release capsules):
    
    • Adults and teenagers—One capsule or 105 milligrams (mg) once a day, taken 30 to 60 minutes before the morning meal.
    
    
    • Children younger than 12 years of age—Use is not recommended.
    
    
  
  
  • For oral dosage form (tablets):
    
    • Adults—One tablet or 35 milligrams (mg) two or three times a day, taken one hour before meals. Your doctor may adjust your dose as needed. However, the dose is usually not more than 2 tablets three times a day.
    
    
    • Children—Use and dose must be determined by your doctor.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using Bontril Slow-Release

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and does not cause any unwanted effects.

Do not use phendimetrazine if you are also using similar medicines such as benzphetamine, diethylpropion, mazindol, phentermine, Didrex®, or Suprenza™. Also, do not use this medicine if you have used an MAO inhibitor (MAOI) such as Eldepryl®, Marplan®, Nardil®, or Parnate® within the past 14 days. Using these medicines together may cause serious unwanted effects.

Make sure your doctor knows if you are pregnant or planning to become pregnant before using this medicine.

This medicine may be habit-forming. If you think this medicine is not working properly after you have taken it for a few weeks, do not increase the dose. Instead, check with your doctor.

Stop using this medicine and check with your doctor right away if you notice a decrease in your ability to exercise, if you faint, or if you have chest pain, swelling of your feet or lower legs, or trouble with breathing. These may be symptoms of a very serious heart or lung problem.

This medicine may cause some people to become dizzy, lightheaded, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or not alert.

For diabetic patients: This medicine may affect blood sugar levels. If you notice a change in the results of your blood or urine sugar tests or if you have any questions, check with your doctor.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription and nonprescription (over-the-counter) medicines, dietary supplements, herbal remedies, or medicines for appetite control, asthma, colds, cough, hay fever, and sinus problems.

Bontril Slow-Release Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Rare

• Seeing, hearing, or feeling things that are not there


• severe mental changes

Incidence not known

• Anxiety


• burning while urinating


• difficult or painful urination


• dizziness


• dry mouth


• fast, irregular, pounding, or racing heartbeat or pulse


• feeling of warmth


• headache


• hyperventilation


• increased need to urinate


• irritability


• nervousness


• numbness or tingling in the arms or legs


• passing urine more often


• redness of the face, neck, arms, and occasionally, upper chest


• restlessness


• shakiness in the legs, arms, hands, or feet


• shortness of breath


• sweating


• trembling or shaking of the hands or feet


• trouble sleeping


• trouble thinking, speaking, or walking


• weakness

Get emergency help immediately if any of the following symptoms of overdose occur:

Symptoms of overdose

• Abdominal or stomach cramps


• blurred vision


• change in consciousness


• convulsions


• diarrhea


• discouragement


• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position


• fainting


• fast, slow, or irregular heartbeat


• feeling sad or empty


• lack of appetite


• lightheadedness


• loss of consciousness


• loss of interest or pleasure


• nausea


• overactive reflexes


• panic


• physical attempt to injure


• pounding in the ears


• rapid breathing


• sweating


• tiredness


• trouble concentrating


• unusual tiredness or weakness


• violent actions


• vomiting

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

• Decreased interest in sexual intercourse


• difficulty having a bowel movement (stool)


• inability to have or keep an erection


• increased in sexual ability, desire, drive, or performance


• increased interest in sexual intercourse


• loss in sexual ability, desire, drive, or performance


• sleeplessness


• stomach pain


• unable to sleep

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Zomig

See also: Generic Zomig-ZMT

Zomig is a brand name of zolmitriptan, approved by the FDA in the following formulation(s):

ZOMIG (zolmitriptan - spray; nasal)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: September 30, 2003
  
  Strength(s): 5MG/SPRAY ^[RLD]

ZOMIG (zolmitriptan - tablet; oral)

• 
  Manufacturer: IPR
  
  Approval date: November 25, 1997
  
  Strength(s): 2.5MG, 5MG ^[RLD]

Has a generic version of Zomig been approved?

No. There is currently no therapeutically equivalent version of Zomig available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Indolyl compounds for treating migraine
  Patent 5,466,699
  Issued: November 14, 1995
  Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
  Assignee(s): Burroughs Wellcome Co.
  ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
  
  Patent expiration dates:
  
  
  • November 14, 2012
    
  
  
  
  • November 14, 2012
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  
  
  • May 14, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Therapeutic heterocyclic compounds
  Patent 5,863,935
  Issued: January 26, 1999
  Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
  Assignee(s): Zeneca Limited
  ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
  
  Patent expiration dates:
  
  
  • November 14, 2012
    
  
  
  
  • May 14, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations containing zolmitriptan
  Patent 6,750,237
  Issued: June 15, 2004
  Inventor(s): Alan Roy; Dearn & Sarah Louise; Williamson & Simon John; Summers & Trevor John; Coomber
  Assignee(s): AstraZeneca AB
  A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
  
  Patent expiration dates:
  
  
  • November 28, 2020
    
    ✓ 
    Drug product
  
  
  
  • May 28, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations containing zolmitriptan
  Patent 7,220,767
  Issued: May 22, 2007
  Inventor(s): Dearn; Alan Roy & Williamson; Sarah Louise & Summers; John Simon & Coomber; Trevor John
  Assignee(s): AstraZeneca AB
  A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
  
  Patent expiration dates:
  
  
  • November 28, 2020
    
    ✓ 
    Drug product
  
  
  
  • May 28, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zomig Consumer Information (Drugs.com)
• Zomig Consumer Information (Wolters Kluwer)
• Zomig Spray Consumer Information (Wolters Kluwer)
• Zomig Consumer Information (Cerner Multum)
• Zomig nasal Consumer Information (Cerner Multum)
• Zomig Advanced Consumer Information (Micromedex)
• Zomig AHFS DI Monographs (ASHP)
• Zolmitriptan Consumer Information (Wolters Kluwer)
• Zolmitriptan Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Zolmitriptan Spray Consumer Information (Wolters Kluwer)
• Zolmitriptan Consumer Information (Cerner Multum)
• Zolmitriptan nasal Consumer Information (Cerner Multum)
• Zolmitriptan Advanced Consumer Information (Micromedex)
• Zolmitriptan AHFS DI Monographs (ASHP)

Liferol

Liferol may be available in the countries listed below.

Ingredient matches for Liferol

Formoterol

Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Liferol in the following countries:

• Italy

International Drug Name Search

Shiomarin

Shiomarin may be available in the countries listed below.

Ingredient matches for Shiomarin

Latamoxef

Latamoxef disodium salt (a derivative of Latamoxef) is reported as an ingredient of Shiomarin in the following countries:

• Japan


• Taiwan

International Drug Name Search

Gront

Gront may be available in the countries listed below.

Ingredient matches for Gront

Cilostazol

Cilostazol is reported as an ingredient of Gront in the following countries:

• Japan

International Drug Name Search

Ivomec D

Ivomec D may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Ivomec D

Clorsulon

Clorsulon is reported as an ingredient of Ivomec D in the following countries:

• France

Ivermectin

Ivermectin is reported as an ingredient of Ivomec D in the following countries:

• France

International Drug Name Search

CO Paroxetine

CO Paroxetine may be available in the countries listed below.

Ingredient matches for CO Paroxetine

Paroxetine

Paroxetine is reported as an ingredient of CO Paroxetine in the following countries:

• Canada

International Drug Name Search

Advocate

Advocate may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Advocate

Imidacloprid

Imidacloprid is reported as an ingredient of Advocate in the following countries:

• Australia


• Austria


• France


• Germany


• New Zealand


• Norway


• Sweden


• Switzerland

Moxidectin

Moxidectin is reported as an ingredient of Advocate in the following countries:

• Australia


• Austria


• France


• Germany


• New Zealand


• Norway


• Sweden


• Switzerland

International Drug Name Search

Calciretard

Calciretard may be available in the countries listed below.

Ingredient matches for Calciretard

Amino Acids

Aspartic Acid calcium (a derivative of Aspartic Acid) is reported as an ingredient of Calciretard in the following countries:

• Germany

International Drug Name Search

Kof-Kontrol

Kof-Kontrol may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Kof-Kontrol

Ammonium Chloride

Ammonium Chloride is reported as an ingredient of Kof-Kontrol in the following countries:

• Australia

International Drug Name Search

Sonalent

Sonalent may be available in the countries listed below.

Ingredient matches for Sonalent

Azelaic Acid

Azelaic Acid is reported as an ingredient of Sonalent in the following countries:

• Greece

International Drug Name Search

Olanzapine Mylan

Olanzapine Mylan may be available in the countries listed below.

Ingredient matches for Olanzapine Mylan

Olanzapine

Olanzapine is reported as an ingredient of Olanzapine Mylan in the following countries:

• Greece


• Slovakia

International Drug Name Search

Amoxicilina + Ácido Clavulânico Ciclum

Amoxicilina + Ácido Clavulânico Ciclum may be available in the countries listed below.

Ingredient matches for Amoxicilina + Ácido Clavulânico Ciclum

Amoxicillin

Amoxicillin is reported as an ingredient of Amoxicilina + Ácido Clavulânico Ciclum in the following countries:

• Portugal

Clavulanate

Clavulanic Acid is reported as an ingredient of Amoxicilina + Ácido Clavulânico Ciclum in the following countries:

• Portugal

International Drug Name Search

Avalide

Avalide is a brand name of hydrochlorothiazide/irbesartan, approved by the FDA in the following formulation(s):

AVALIDE (hydrochlorothiazide; irbesartan - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS
  
  Approval date: September 30, 1997
  
  Strength(s): 12.5MG;150MG ^[RLD]


• 
  Manufacturer: SANOFI AVENTIS
  
  Approval date: August 31, 1998
  
  Strength(s): 12.5MG;300MG
  

Has a generic version of Avalide been approved?

No. There is currently no therapeutically equivalent version of Avalide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avalide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
  Patent 5,270,317
  Issued: December 14, 1993
  Inventor(s): Bernhart; Claude & Breliere; Jean-Claude & Clement; Jacques & Nisato; Dino & Perreault; Pierre & Muneaux; Claude & Muneaux; Yvette
  Assignee(s): Elf Sanofi
  The invention relates to N-substituted heterocyclic derivatives and its salts. These derivatives have the formula ##STR1## in which the substituents are as defined in the specification. Application: Angiotensin II antagonists
  
  Patent expiration dates:
  
  
  • September 30, 2011
    
  
  
  
  • September 30, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 30, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing irbesartan
  Patent 5,994,348
  Issued: November 30, 1999
  Inventor(s): Ku; Cathy C. & Sprockel; Omar L. & Lang; Beth A. & Desai; Divyakant S.
  Assignee(s): Sanofi
  Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.
  
  Patent expiration dates:
  
  
  • June 7, 2015
    
  
  
  
  • June 7, 2015
    
    ✓ 
    Drug product
  
  
  
  • December 7, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 16, 2010 - USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
  
  

See also...

• Avalide Consumer Information (Drugs.com)
• Avalide Consumer Information (Wolters Kluwer)
• Avalide Consumer Information (Cerner Multum)
• Avalide Advanced Consumer Information (Micromedex)
• Irbesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and irbesartan Consumer Information (Cerner Multum)
• Irbesartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Dopadone

Dopadone may be available in the countries listed below.

Ingredient matches for Dopadone

Domperidone

Domperidone is reported as an ingredient of Dopadone in the following countries:

• Bangladesh

International Drug Name Search

Argimate

Argimate may be available in the countries listed below.

Ingredient matches for Argimate

Arginine

Arginine glutamate (a derivative of Arginine) is reported as an ingredient of Argimate in the following countries:

• Japan

International Drug Name Search

Klarmedic

Klarmedic may be available in the countries listed below.

Ingredient matches for Klarmedic

Clarithromycin

Clarithromycin is reported as an ingredient of Klarmedic in the following countries:

• Peru

International Drug Name Search

Tocoferole Acetat

Tocoferole Acetat may be available in the countries listed below.

Ingredient matches for Tocoferole Acetat

Tocopherol, α-

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Tocoferole Acetat in the following countries:

• Georgia

International Drug Name Search

Caniphedrin

Caniphedrin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Caniphedrin

Ephedrine

Ephedrine hydrochloride (a derivative of Ephedrine) is reported as an ingredient of Caniphedrin in the following countries:

• Germany


• Switzerland

International Drug Name Search

Lomper

Lomper may be available in the countries listed below.

Ingredient matches for Lomper

Mebendazole

Mebendazole is reported as an ingredient of Lomper in the following countries:

• Spain

International Drug Name Search

Eyeflur

Eyeflur may be available in the countries listed below.

Ingredient matches for Eyeflur

Flurbiprofen

Flurbiprofen sodium salt (a derivative of Flurbiprofen) is reported as an ingredient of Eyeflur in the following countries:

• Greece

International Drug Name Search

Gonal-f

See also: Generic Gonal-f RFF, Generic Gonal-f RFF Pen

Gonal-f is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):

GONAL-F (follitropin alfa/beta - injectable; subcutaneous)

• 
  Manufacturer: EMD SERONO
  
  Approval date: February 28, 2001
  
  Strength(s): 1,050 IU/VIAL
  


• 
  Manufacturer: EMD SERONO
  
  Approval date: March 26, 2004
  
  Strength(s): 450 IU/VIAL ^[RLD]

Has a generic version of Gonal-f been approved?

No. There is currently no therapeutically equivalent version of Gonal-f available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gonal-f. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Follicle stimulating hormone and pharmaceutical compositions containing same
  Patent 5,767,067
  Issued: June 16, 1998
  Inventor(s): Arpaia; Guiseppe & Serani; Serenella & Sirna; Antonino & Villa; Stefano
  Assignee(s): Istituto di Ricerca Cesare Serono S.p.A.
  Purification of human FSH from post-menopausal urine gonadogropin using immunochromatography and reverse phase HPLC steps yelds a biologically active hormone which is free from detectable traces of LH and other urinary proteins.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
  Patent 5,767,251
  Issued: June 16, 1998
  Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
  Assignee(s): Genzyme Corporation
  Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  FSH and FSH variant formulations, products and methods
  Patent 7,563,763
  Issued: July 21, 2009
  Inventor(s): Hoffmann; James Arthur & Lu; Jirong
  Assignee(s): Ares Trading S.A.
  This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
  
  Patent expiration dates:
  
  
  • August 23, 2019
    
    ✓ 
    Drug product
  
  

See also...

• Gonal-f Powder Consumer Information (Wolters Kluwer)
• Gonal-F Consumer Information (Cerner Multum)
• Gonal-F Advanced Consumer Information (Micromedex)
• Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
• Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
• Follitropin Beta Consumer Information (Wolters Kluwer)
• Follicle stimulating hormone Consumer Information (Cerner Multum)
• Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
• Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)

Retarbolin

Retarbolin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Retarbolin

Nandrolone

Nandrolone 17ß-cyclohexylpropionate (a derivative of Nandrolone) is reported as an ingredient of Retarbolin in the following countries:

• United Kingdom

International Drug Name Search

Flagyl ER

See also: Generic Flagyl

Flagyl ER is a brand name of metronidazole, approved by the FDA in the following formulation(s):

FLAGYL ER (metronidazole - tablet, extended release; oral)

• 
  Manufacturer: GD SEARLE LLC
  
  Approval date: November 26, 1997
  
  Strength(s): 750MG ^[RLD][AB]

Has a generic version of Flagyl ER been approved?

A generic version of Flagyl ER has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Flagyl ER and have been approved by the FDA:

metronidazole tablet, extended release; oral

• 
  Manufacturer: ALEMBIC LTD
  
  Approval date: May 5, 2010
  
  Strength(s): 750MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flagyl ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Modified-release metronidazole compositions and methods for making and using same
  Patent 6,103,262
  Issued: August 15, 2000
  Inventor(s): Desai; Subhash & Mancini; Alan Mark & Schumann; Steven Charles
  Assignee(s): G. D. Searle & Company
  Pharmaceutical compositions having a modified release profile for once daily dosing of metronidazole, methods for making the pharmaceutical compositions, and methods for treating a microbial infection with once daily dosing of the pharmaceutical compositions of the invention are provided. The compositions given once daily exhibit substantial bioequivalence to immediate release metronidazole given three times per day. The compositions of the invention comprise: (a) a first portion of metronidazole which is about 59 wt % to about 79 wt % metronidazole; (b) about 1.5 wt % to about 3.0 wt % of an aqueous insoluble poly(meth)acrylic acid ester copolymer which is aqueous permeable, aqueous expandable and pH-independent; (c) about 0.1 wt % to about 2.0 wt % detackifier; (d) 0 to about 23 wt % of a first aqueous soluble pharmaceutical diluent; (e) 0 to about 23 wt % of a second aqueous soluble diluent which is suitable for forming a pharmaceutical tablet when compressed with the granules of (a), the second aqueous soluble diluent being the same as or different from the first aqueous soluble diluent; (f) 0 to about 20 wt % of a second portion of metronidazole; (g) 0 to about 0.2 wt % glidant; and (h) 0 to about 2 wt % lubricant; wherein the composition comprises metronidazole containing granules comprising (a), (b), (c) and (d), wherein the sum of the weight percentages of metronidazole provided by (a) and (f) is between about 72 wt % and about 79 wt %, and wherein the sum of the weight percentages of the aqueous soluble diluent provided by (d) and (e) is between about 16 wt % and about 23 wt %.
  
  Patent expiration dates:
  
  
  • August 15, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL VAGINOSIS
    ✓ 
    Drug product
  
  

See also...

• Flagyl ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Flagyl ER Consumer Information (Cerner Multum)
• Flagyl ER Advanced Consumer Information (Micromedex)
• Metronidazole Consumer Information (Drugs.com)
• Metronidazole Consumer Information (Wolters Kluwer)
• Metronidazole Capsules Consumer Information (Wolters Kluwer)
• Metronidazole Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Metronidazole Tablets Consumer Information (Wolters Kluwer)
• Metronidazole Consumer Information (Cerner Multum)
• Flagyl I.V. RTU Advanced Consumer Information (Micromedex)
• Flagyl I.V. RTU Intravenous Advanced Consumer Information (Micromedex)
• Metronidazole Intravenous Advanced Consumer Information (Micromedex)
• Metronidazole Oral, Intravenous Advanced Consumer Information (Micromedex)
• Metronidazole AHFS DI Monographs (ASHP)
• Metronidazole Hydrochloride AHFS DI Monographs (ASHP)

Bimotrim

Bimotrim may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bimotrim

Sulfadoxine

Sulfadoxine is reported as an ingredient of Bimotrim in the following countries:

• Luxembourg


• Sweden


• United Kingdom

Trimethoprim

Trimethoprim is reported as an ingredient of Bimotrim in the following countries:

• Luxembourg


• Sweden


• United Kingdom

International Drug Name Search

Avinza

Avinza is a brand name of morphine, approved by the FDA in the following formulation(s):

AVINZA (morphine sulfate - capsule, extended release; oral)

• 
  Manufacturer: KING PHARMS
  
  Approval date: March 20, 2002
  
  Strength(s): 120MG ^[RLD], 90MG
  


• 
  Manufacturer: KING PHARMS
  
  Approval date: December 18, 2008
  
  Strength(s): 45MG, 75MG
  

Has a generic version of Avinza been approved?

No. There is currently no therapeutically equivalent version of Avinza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avinza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral morphine multiparticulate formulation
  Patent 6,066,339
  Issued: May 23, 2000
  Inventor(s): Stark; Paul & Cunningham; Sean & Moodley; Jagathesan
  Assignee(s): Elan Corporation, plc
  An oral morphine multiparticulate formulation for once-daily administration to a patient, comprising sustained release particles each having a core containing water soluble morphine and an osmotic agent, the core being coated with a rate-controlling polymer coat comprised of ammonio methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of morphine over at least 24 hours in the patient.
  
  Patent expiration dates:
  
  
  • November 25, 2017
    
  
  
  
  • November 25, 2017
    
    ✓ 
    Drug product
  
  

See also...

• Avinza Consumer Information (Drugs.com)
• Avinza Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Avinza Consumer Information (Cerner Multum)
• Avinza Advanced Consumer Information (Micromedex)
• Morphine Consumer Information (Drugs.com)
• Morphine Concentrate Consumer Information (Wolters Kluwer)
• Morphine Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Morphine Immediate-Release Consumer Information (Wolters Kluwer)
• Morphine Immediate-Release Tablets Consumer Information (Wolters Kluwer)
• Morphine Soluble Tablets Consumer Information (Wolters Kluwer)
• Morphine Solution Consumer Information (Wolters Kluwer)
• Morphine Suppositories Consumer Information (Wolters Kluwer)
• Morphine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Morphine IR Consumer Information (Cerner Multum)
• Morphine Consumer Information (Cerner Multum)
• DepoDur Advanced Consumer Information (Micromedex)
• Morphine Advanced Consumer Information (Micromedex)
• Morphine Epidural Advanced Consumer Information (Micromedex)
• Morphine Injection Advanced Consumer Information (Micromedex)
• Morphine Sulfate AHFS DI Monographs (ASHP)

Nuvigil

Nuvigil is a brand name of armodafinil, approved by the FDA in the following formulation(s):

NUVIGIL (armodafinil - tablet; oral)

• 
  Manufacturer: CEPHALON
  
  Approval date: June 15, 2007
  
  Strength(s): 150MG, 250MG ^[RLD], 50MG
  

Has a generic version of Nuvigil been approved?

No. There is currently no therapeutically equivalent version of Nuvigil available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuvigil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
  Patent 7,132,570
  Issued: November 7, 2006
  Inventor(s): Neckebrock; Olivier & Leproust; Pierre
  Assignee(s): Cephalon France
  The invention relates to a process for the preparation of crystalline forms of the optical enantiomers of modafinil, comprising stages comprising: i) dissolving one of the optical enantiomers of modafinil in a solvent other than ethanol, ii) crystallising the modafinil enantiomer, iii) recovering the crystalline form of the modafinil enantiomer so obtained. The invention also relates to a process for the preparation of the optical enantiomers of modafinil.
  
  Patent expiration dates:
  
  
  • December 18, 2023
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 18, 2024
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations of modafinil
  Patent 7,297,346
  Issued: November 20, 2007
  Inventor(s): Corvari; Vincent & Grandolfi; George & Parikh; Alpa
  Assignee(s): Cephalon Inc.
  The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
  
  Patent expiration dates:
  
  
  • November 29, 2023
    
    ✓ 
    Drug product
  
  
  
  • May 29, 2024
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Acetamide derivative having defined particle size
  Patent RE37516
  Issued: January 15, 2002
  Inventor(s): Peter E.; Grebow & Vincent; Corvari & David; Stong
  Assignee(s): Cephalon, Inc.
  Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.
  
  Patent expiration dates:
  
  
  • October 6, 2014
    
    ✓ 
    Patent use: IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
    ✓ 
    Drug product
  
  
  
  • April 6, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Nuvigil Consumer Information (Drugs.com)
• Nuvigil Consumer Information (Wolters Kluwer)
• Nuvigil Consumer Information (Cerner Multum)
• Nuvigil Advanced Consumer Information (Micromedex)
• Nuvigil AHFS DI Monographs (ASHP)
• Armodafinil Consumer Information (Wolters Kluwer)
• Armodafanil Consumer Information (Cerner Multum)
• Armodafinil Consumer Information (Cerner Multum)
• Armodafinil Advanced Consumer Information (Micromedex)
• Armodafinil AHFS DI Monographs (ASHP)

Clofamox

Clofamox may be available in the countries listed below.

Ingredient matches for Clofamox

Amoxicillin

Amoxicillin is reported as an ingredient of Clofamox in the following countries:

• Argentina

International Drug Name Search

Etoposide

In the US, Etoposide (etoposide systemic) is a member of the drug class mitotic inhibitors and is used to treat Cancer, Hodgkin's Lymphoma, Ovarian Cancer, Small Cell Lung Cancer and Testicular Cancer.

US matches:

• Etoposide


• Etoposide Capsules


• Etoposide phosphate


• Etoposide Oral, Intravenous


• Etoposide Capsule

UK matches:

• Etoposide 20 mg/ml Injection (SPC)

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01CB01

CAS registry number (Chemical Abstracts Service)

0033419-42-0

Chemical Formula

C29-H32-O13

Molecular Weight

588

Therapeutic Category

Antineoplastic agent

Chemical Name

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-ß-D-glucopyranoside)

Foreign Names

• Etoposidum (Latin)
• Etoposid (German)
• Etoposide (French)
• Etoposido (Spanish)

Generic Names

• Etoposide (OS: JAN, USAN, DCIT, BAN)
• Étoposide (OS: DCF)
• EPE (IS)
• VP 16213 (IS: Bristol-Myers)
• Etoposid (PH: Ph. Eur. 6)
• Etoposide (PH: BP 2010, Ph. Int. 4, USP 32, Ph. Eur. 6)
• Etoposidum (PH: Ph. Int. 4, Ph. Eur. 6)
• Etoposide Phosphate (OS: USAN)
• BMY 40481 (IS: Bristol-Myers)

Brand Names

• Celltop
  Baxter, Belgium; Baxter, France



• Cryosid
  Cryopharma, Mexico



• Ebeposid
  Ebewe, Slovenia



• Eposin
  Emporio, Slovenia; Med, Turkey; Medac, United Arab Emirates; Medac, Bahrain; Medac, Egypt; Medac, United Kingdom; Medac, Iraq; Medac, Iran; Medac, Jordan; Medac, Kuwait; Medac, Lebanon; Medac, Oman; Medac, Qatar; Medac, Saudi Arabia; Medac, Syria; Medac, Yemen; Pharmachemie, Sri Lanka; Pharmachemie, Malaysia; Pharmachemie, Taiwan; Pharmachemie, South Africa; Tedec Meiji, Spain; Teva, Belgium; Teva, Norway; Teva, Sweden



• Epsidox
  Chile, Chile



• Etobion
  Medicus, Greece



• Eto-cell
  Cell pharm, Germany



• Etocris
  LKM, Argentina



• Eto-GRY
  Teva-Gry, Germany



• Etomedac
  Medac, Germany; Medac, Luxembourg



• Etonco
  Armstrong, Mexico



• Etonolver
  Nolver, Venezuela



• Etoposid Ebewe
  Ebewe, Austria; Ebewe, Estonia; Ebewe, Hungary; Ebewe, Indonesia; Ebewe, Israel; Ebewe, Lithuania; Ebewe, Luxembourg; Ebewe, Latvia; Ebewe, Poland; Ebewe, Romania; Ebewe, Serbia; Ebewe, Russian Federation; Ebewe, Tunisia; Ferron, Indonesia; Liba, Turkey; Sandoz, Switzerland



• Etoposid Hexal
  Hexal, Germany



• Etoposid Meda
  Meda, Denmark; Meda, Sweden



• Etoposid Pfizer
  Pfizer, Austria; Pfizer, Georgia



• Etoposid Sandoz
  Sandoz, Germany



• Etoposid
  Meda, Norway



• Etoposide Actavis
  Sindan, Bulgaria



• Etoposide Aeon
  Aeon, Greece



• Etoposide APP
  Abraxis, Switzerland



• Etoposide Crinos
  Crinos, Italy



• Etoposide DBL
  Hospira, Indonesia; Hospira, Singapore; Mayne, Hong Kong; Tempo Scan Pacific, Indonesia



• Etoposide Ebewe
  Ebewe, Belgium; Ebewe, Bulgaria; Ebewe, Georgia; Ebewe, Italy; Ebewe, Myanmar; Ebewe, Vietnam; Pharmanel, Greece; Würth, Croatia (Hrvatska)



• Etoposide Fidia
  Fidia, Italy



• Etoposide Injection
  Hospira, Australia; Mayne, New Zealand; PfizerPerth, Australia



• Etoposide Merck
  Merck Génériques, Tunisia



• Etoposide Mylan
  Mylan, France



• Etoposide Pfizer
  Pfizer, Switzerland; Pfizer, Denmark; Pfizer, Finland; Pfizer, Philippines; Pfizer, Singapore



• Etoposide Pharmachemie
  Chemipharm, Greece



• Etoposide Pharmacia
  Pfizer, Vietnam



• Etoposide Pierre Fabre
  PF, Luxembourg; Pierre Fabre, Romania



• Etoposide Teva
  Med, Turkey; Pharmachemie, Bulgaria; Teva, Czech Republic; Teva, Hungary; Teva, Lithuania; Teva, Latvia; Teva, Slovakia; Teva Santé, France; Teva-NL, Italy



• Etoposide
  Accord, United States; APP, United States; Atafarm, Turkey; Bedford, United States; Genpharm, United States; Hospira, United States; Marsam, United States; Mediline, Israel; Mylan, United States; Pfizer, Croatia (Hrvatska); Pfizer, Serbia; Pharmachemie, United States; SuperGen, United States; Teva, Israel



• Etoposide-Mayne
  Mayne, Luxembourg



• Etoposid-Lens
  Verofarm, Georgia



• Etoposido Biocrom
  Biocrom, Argentina



• Etoposido Centam
  Centrum, Spain



• Etoposido Delta Farma
  Delta Farma, Argentina



• Etoposido Ferrer Farma
  Ferrer, Spain



• Etoposido Filaxis
  Filaxis, Argentina



• Etoposido GP Pharm
  GP Pharm, Peru



• Etoposido Microsules
  Microsules, Argentina



• Etoposido Pfizer
  Pfizer, Peru



• Etoposido Rontag
  Rontag, Argentina



• Etoposido Servycal
  Servycal, Argentina; Servycal, Peru



• Etoposido Smaller
  Smaller, Spain



• Etoposido Teva
  Teva, Spain



• Etoposido Varifarma
  Varifarma, Argentina



• Etoposido World Pharma
  World Pharma, Peru



• Etoposido
  Baxter, Chile; Bestpharma, Chile; Kampar, Chile; Pfizer, Chile



• Etoposid-Teva
  Teva Pharma, Switzerland



• Etopul
  Korea United Pharm, Georgia; Novell, Indonesia



• Etosid
  Cemelog-BRS, Bulgaria; Cipla, India; Pharmaceutical, Venezuela



• Euvaxon
  Teva, Argentina



• Fytosid
  Biogalenic, Venezuela; Dabur, Georgia; Dabur, Sri Lanka; Dabur, Myanmar; Dabur, Philippines



• Lastet
  Cancernova, Germany; Euro Nippon Kayaku, Poland; Khandelwal, India; Nippon, Bulgaria; Nippon Kayaku, Bulgaria; Nippon Kayaku, Czech Republic; Nippon Kayaku, Georgia; Nippon Kayaku, Hungary; Nippon Kayaku, Japan; Nippon Kayaku, Latvia; Nippon Kayaku, Oman; Nippon Kayaku, Serbia; Nippon Kayaku, Taiwan; Onko-Koçsel, Turkey; Pfizer, Chile; Refasa, Peru



• Lastet S
  Nippon Kayaku, Japan



• Neoplaxol
  Richmond, Argentina; Richmond, Peru



• Neoposid
  NeoCorp, Germany



• Oncoposido
  Biotoscana, Colombia



• P&U Etoposide
  Pfizer, South Africa



• Percas
  Ivax, Argentina



• Posyd
  Combiphar, Indonesia; Pharmachemie, Indonesia



• Riboposid
  Hikma, Germany



• Sintopozid
  Actavis, Hungary; Sindan, Poland; Sindan, Romania



• Toposar
  Pfizer, United States



• Toposide
  Pharmacia & Upjohn, Romania



• Toposin
  Pharmachemie, Netherlands



• VepeGal
  Galenika, Serbia



• Vepesid
  Bristol-Myers Squibb, Argentina; Bristol-Myers Squibb, Austria; Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Bosnia & Herzegowina; Bristol-Myers Squibb, Belgium; Bristol-Myers Squibb, Brazil; Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Colombia; Bristol-Myers Squibb, Czech Republic; Bristol-Myers Squibb, Czech Republic; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, Denmark; Bristol-Myers Squibb, Estonia; Bristol-Myers Squibb, Spain; Bristol-Myers Squibb, Finland; Bristol-Myers Squibb, United Kingdom; Bristol-Myers Squibb, Georgia; Bristol-Myers Squibb, Greece; Bristol-Myers Squibb, Hong Kong; Bristol-Myers Squibb, Hungary; Bristol-Myers Squibb, Ireland; Bristol-Myers Squibb, Italy; Bristol-Myers Squibb, Japan; Bristol-Myers Squibb, Lithuania; Bristol-Myers Squibb, Luxembourg; Bristol-Myers Squibb, Mexico; Bristol-Myers Squibb, Netherlands; Bristol-Myers Squibb, Norway; Bristol-Myers Squibb, New Zealand; Bristol-Myers Squibb, Philippines; Bristol-Myers Squibb, Poland; Bristol-Myers Squibb, Portugal; Bristol-Myers Squibb, Romania; Bristol-Myers Squibb, Serbia; Bristol-Myers Squibb, Russian Federation; Bristol-Myers Squibb, Sweden; Bristol-Myers Squibb, Slovenia; Bristol-Myers Squibb, Slovakia; Bristol-Myers Squibb, Thailand; Bristol-Myers Squibb, Turkey; Bristol-Myers Squibb, Taiwan; Bristol-Myers Squibb, United States; Bristol-Myers Squibb, South Africa; Er-Kim, Turkey; Medcor, Netherlands; PharmaSwiss, Croatia (Hrvatska)



• Vépéside
  Novartis, Tunisia



• VP-16
  Bristol-Myers Squibb, Chile



• VP-Gen
  Bioprofarma, Argentina



• Etopofos
  Bristol-Myers Squibb, Austria; Bristol-Myers Squibb, Denmark; Bristol-Myers Squibb, Finland; Bristol-Myers Squibb, Norway; Bristol-Myers Squibb, Sweden



• Etopophos
  Bristol-Myers Squibb, United Arab Emirates; Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Bahrain; Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Cote D'ivoire; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, Egypt; Bristol-Myers Squibb, France; Bristol-Myers Squibb, Gabon; Bristol-Myers Squibb, United Kingdom; Bristol-Myers Squibb, Guinea; Bristol-Myers Squibb, Iraq; Bristol-Myers Squibb, Iran; Bristol-Myers Squibb, Jordan; Bristol-Myers Squibb, Kuwait; Bristol-Myers Squibb, Lebanon; Bristol-Myers Squibb, Luxembourg; Bristol-Myers Squibb, Mali; Bristol-Myers Squibb, Niger; Bristol-Myers Squibb, New Zealand; Bristol-Myers Squibb, Oman; Bristol-Myers Squibb, Qatar; Bristol-Myers Squibb, Saudi Arabia; Bristol-Myers Squibb, Senegal; Bristol-Myers Squibb, Syria; Bristol-Myers Squibb, Chad; Bristol-Myers Squibb, Togo; Bristol-Myers Squibb, United States; Bristol-Myers Squibb, Yemen; Bristol-Myers Squibb, South Africa



• Nexvep
  Bristol-Myers Squibb, Brazil



• Vépéside
  Genopharm, France

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
SPC	Summary of Product Characteristics (UK)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.